1. Introduction {#sec1}
===============

During the course of HIV-1 infection, multifactorial T-lymphocyte (T-cell)-mediated mechanisms contribute to the progressive loss of host immune function \[[@B25]--[@B31]\]. In infected individuals, immune dysregulation occurs early and is characterized by a decrease in CD4+ cell count, a concurrent rise in CD8+ cells, a progressive decline in the CD4+/CD8+ ratio, and defective thymocyte proliferation \[[@B11]\]. During late-stage disease, loss of T-cell homeostasis also occurs \[[@B27], [@B33]\].

T cells are chronically activated throughout the course of HIV infection, as indicated by an increase in the expression of the antigens Ki67, CD38, and human leukocyte antigen (HLA)-DR, with CD38 recognized as the most reliable marker of immune activation \[[@B25]--[@B14], [@B31], [@B24]\]. Immune activation provides the virus with a steady pool of target cells and has been linked with increased polyclonal T-cell proliferation and turnover, as well as increases in the apoptotic marker CD95 \[[@B2]--[@B37]\] and activation-induced cell death \[[@B34], [@B7]--[@B20]\].

Concomitant with the decline of CD4 cells in the peripheral blood, the frequency of the CD4+ CD28 null subset increases with disease progression and eventual progression to AIDS \[[@B2]\]. The presence of CD28 on T cells is critically important for the generation of T-cell responses. Interaction of this costimulatory molecule with its ligands increases the expression of antiapoptotic proteins and improves interleukin (IL)-2 production. The increase in circulation of T cells with a CD4+ CD28 null phenotype is consistent with a process known as replicative senescence \[[@B3], [@B37], [@B41]--[@B36]\]. T cells that lack CD28 surface expression are nonanergic, oligoclonally expanded, and terminally differentiated, with limited replicative capacity and increased sensitivity to apoptosis \[[@B5], [@B44]\]. These alterations in phenotype are accompanied by cytokine changes consistent with a chronic proinflammatory state. The failure to produce adequate amounts of IL-2 leads to a marked functional impairment of cellular and humoral immunity. Reduced IL-2 expression has been associated with a shift from Th1 cytokine responses to Th2 cytokine responses. It has been postulated that the Th1/Th2 imbalance may result in cellular immunity deficiency \[[@B26]\].

The dysregulation of cytokine secretion during the course of HIV infection has been examined using a wide range of methods, including enzyme-linked immunosorbent assay, reverse transcriptase-polymerase chain reaction, T-cell cloning, and, more recently, flow cytometric intracellular cytokine detection \[[@B26]\]. Of these methods, only flow cytometry allows quantitative and qualitative determination of cytokine expression patterns in individual T cells \[[@B26]\].

Successful antiretroviral (ARV) therapy results in improvements in circulating CD4+ T-cell levels with decreases in CD8+ counts and declines in immune activation and CD95 expression \[[@B25]--[@B31], [@B27], [@B24], [@B15]--[@B6]\]. Limited data on replicative senescence suggest a lack of significant improvement in the short term, despite adequate HIV suppression \[[@B2]\]. Some studies have suggested that protease inhibitor- (PI-) based regimens may have a greater effect on CD4+ count recovery than nonnucleoside reverse transcriptase inhibitor-based regimens \[[@B16], [@B39]\]. Some of the previous studies on immune recovery with ARV therapy have been cross-sectional in design, conducted primarily in white males, and focused on absolute CD4+ count or CD4+% recovery. Furthermore, most of these studies did not comprehensively assess the functional aspects of immune recovery \[[@B38]\]. Of the studies that did evaluate the influence of ARV therapy on functional immune parameters, most were drug class specific \[[@B32]--[@B8]\].

GRACE (Gender, Race, And Clinical Experience) is the largest ARV trial to focus on women with HIV-1 in North America and was designed to assess sex-based and race-based differences in efficacy, safety, and tolerability of the PI darunavir with low-dose ritonavir (DRV/r) plus an optimized background regimen over 48 weeks in a diverse, treatment-experienced patient population \[[@B10]\]. The aim of this prospective substudy was to quantitatively and qualitatively evaluate the recovery of functional immunity (T-cell function) with a DRV/r-based regimen in a subset of patients from the GRACE study.

2. Materials and Methods {#sec2}
========================

2.1. Study Design and Patients {#sec2.1}
------------------------------

GRACE was a multicenter, open-label, single-arm, Phase IIIb study conducted at 65 sites across USA, Puerto Rico, and Canada that enrolled 429 treatment-experienced patients (viral load ≥ 1000 HIV-1 RNA copies/mL) aged at least 18 years with documented HIV-1 infection \[[@B10]\]. Full inclusion and exclusion criteria and the study flow diagram have been reported \[[@B10]\]. Patients received DRV/r 600/100 mg twice daily plus an investigator-selected background regimen that could include etravirine. Patients at participating GRACE study sites were eligible for the prospective immunology substudy, which aimed to enroll up to 100 subjects. A group of healthy, HIV seronegative volunteers were included for comparison.

2.2. Ethics Statement {#sec2.2}
---------------------

The research has complied with all federal guidelines and institutional policies. All subjects were required to sign a separate, Independent Ethics Committee/Institutional Review Board (IRB) informed consent form specific to this substudy. The IRBs were Quorom Review Inc., Seattle, WA, Office of Human Research Ethics---UNC IRB, Chapel Hill, NC, and AIDS Research Consortium of Atlanta, Atlanta, GA. Each IRB approved of this study. The study was conducted in accordance with the principles of the Declaration of Helsinki and followed Good Clinical Practice guidelines.

2.3. Study Evaluations {#sec2.3}
----------------------

Viral suppression in this analysis was defined as achieving HIV-1 RNA less than 50 copies/mL at Week 48. Immune function and phenotype were determined by flow cytometry at baseline and Weeks 12 and 48 in virologically suppressed and nonsuppressed patients. Changes in immune phenotype were determined from subsets of CD4+ and CD8+ T cells, with immune activation defined as increased expression of T-cell CD38 and HLA-DR surface markers, and immune replicative senescence by increased frequency of circulating CD28 null T cells. Changes in immune function were assessed by lymphocyte proliferation in response to *Candida* and tetanus (recall antigens), phytohemagglutinin (PHA) and pokeweed (mitogenic plant lectins), and CD3+/CD28+ and by intracellular cytokine expression of IL-2, interferon-gamma (IFN-*γ*), and tumor necrosis factor-alpha (TNF-*α*) in response to staphylococcal enterotoxin B.

2.4. Immunophenotyping {#sec2.4}
----------------------

A whole blood lysing technique was used and subpopulations were assessed according to a standard protocol for 3-color and 4-color immunofluorescence flow cytometry using fluorochrome conjugated monoclonal antibodies and a fluorescence activated cell sorter. A panel of monoclonal antibodies was used to delineate total CD3+, total CD4+ and CD8+ T cells, CD4+/CD8+ ratio, activated T cells (CD38+/HLA-DR+), immune replicative senescence (CD4+/CD28+ or CD8+/CD28+), and apoptotic cells (CD95+).

2.5. Proliferation Assays {#sec2.5}
-------------------------

The Vybrant CFDA SE Cell Tracer Kit (Molecular Probes, Inc.) was used. Lymphocytes were labeled with carboxyfluorescein diacetate and succinimidyl ester CFDA SE and then incubated at 37°C with 5% carbon dioxide for 7 days. The label is inherited by daughter cells after division. Labeled lymphocytes with carboxyfluorescein diacetate and succinimidyl ester were detected by flow cytometry using CD45 markers for gating strategy. This method quantified mitogenic and recall antigen responses. The reagents used were *Candida*, tetanus, CD3+/CD28+, PHA, and pokeweed.

2.6. Intracellular Cytokines {#sec2.6}
----------------------------

Flow cytometric intracellular cytokine detection of Th1 cytokines including IFN-*γ*, IL-2, and TNF-*α* was assessed using the BD Cytofix/Cytoperm Plus Fixation/Permeabilization (GolgiPlug protein transport inhibitor; BD Biosciences). Peripheral blood mononuclear cells were stimulated with staphylococcal enterotoxin B (Sigma) and a CEF control peptide pool (CMV, EBV, Influenza virus; NIH reagent 9808). This stimulation step was followed by the fixation and permeabilization of the cells. Then, surface and intracellular staining antibodies were added in a single staining step (Anti-Hu-IFN-*γ*/CD69/CD4/CD3, Anti-Hu-IL2/CD69/CD4/CD3, Anti-Hu-TNF-*α*/CD69/CD4/CD3; BD Biosciences). Cells were acquired and analyzed by flow cytometry.

2.7. Statistical Analysis {#sec2.7}
-------------------------

Immune recovery was evaluated in continuous and categorical outcome analyses. Wilcoxon rank-sum tests were used to assess immune parameter changes from baseline.

3. Results {#sec3}
==========

3.1. Patient Population and Baseline Characteristics {#sec3.1}
----------------------------------------------------

A total of 32 patients with HIV-1 were enrolled in the substudy; 25 (78%) patients had Week 48 data and 19 (59%) were virologically suppressed at Week 48. The normal comparator group consisted of 34 healthy, HIV-seronegative individuals, 17 (50%) of whom were women and 25 (74%) of whom were white. Patient demographics and baseline characteristics for total and virologically suppressed patients are shown in [Table 1](#tab1){ref-type="table"}.

3.2. Immune Phenotype {#sec3.2}
---------------------

The median (range) CD4+ count at baseline for the total patient population was 191 (2, 463) and the median (range) CD4+ count in virologically suppressed patients at baseline was 222 (2, 398) cells/mm^3^ ([Table 1](#tab1){ref-type="table"}). At Week 48, the median (range) CD4+ count for the total population and virologically suppressed patients was 337 (98, 812) and 398 (119, 812) cells/mm^3^, respectively. In virologically suppressed patients, the CD4+% increased significantly from baseline to Week 48 (*P* \< .03; [Figure 1](#fig1){ref-type="fig"}). The median (range) CD8+ count at baseline for the total patient population was 912.5 (288, 3131) cells/mm^3^, while the median (range) CD8+ count in virologically suppressed patients at baseline was 1037 (288, 3131) cells/mm^3^. The CD8+% decreased significantly from baseline to Week 48 (*P* \< .01) in virologically suppressed patients ([Figure 1](#fig1){ref-type="fig"}). The median (range) CD4+/CD8+ ratio at baseline was 0.22 (0.01, 0.70) in all patients and 0.22 (0.01, 0.70) in virologically suppressed patients. The CD4+/CD8+ ratio at Weeks 12 and 48 is displayed in [Figure 1](#fig1){ref-type="fig"} and [Table 2](#tab2){ref-type="table"}. The CD4+/CD8+ ratio increased significantly from baseline to Week 48 (*P* \< .01) in suppressed patients. The percentage of CD4+ and CD8+ cells at Weeks 12 and 48 in suppressed patients is shown over 48 weeks in [Figure 1](#fig1){ref-type="fig"}. The percentage of CD4+ cells significantly increased (*P* \< .01) and CD8+ cells significantly decreased (*P* = .03) from baseline to Week 48.

Improvements in immune activation, as measured by decreases in CD38 and HLA-DR expression on CD4+ and CD8+ cells over the course of the study, were observed in both the total patient population ([Table 2](#tab2){ref-type="table"}) and in virologically suppressed patients ([Table 2](#tab2){ref-type="table"}; [Figure 2](#fig2){ref-type="fig"}).

The percentage of apoptotic (CD95+) CD4+ cells in suppressed patients significantly increased from baseline to Week 48 (*P* = .0142; [Table 2](#tab2){ref-type="table"}; [Figure 2](#fig2){ref-type="fig"}). The percentage of apoptotic CD8+ cells, on the other hand, significantly decreased from baseline to Week 48 in suppressed patients (*P* = .0025; [Table 2](#tab2){ref-type="table"}; [Figure 2](#fig2){ref-type="fig"}).

Changes in immune replicative senescence were measured by changes in the frequency of CD4+/CD28− or CD8+/CD28− cells ([Table 2](#tab2){ref-type="table"}). There was little change in the expression of costimulatory marker CD28+ on CD4+ cells from baseline to Week 48 in the total patient population or the virologically suppressed group ([Table 2](#tab2){ref-type="table"}). There was a small decrease in the expression of CD28+ on CD8+ cells in the total patient population and the virologically suppressed population from baseline to Week 48 ([Table 2](#tab2){ref-type="table"}).

3.3. Immune Function {#sec3.3}
--------------------

The ability of CD4+ lymphocytes to respond to mitogens and recall antigens improved in GRACE patients over the course of the study. Proliferation in response to CD3+/CD28+ and PHA was at, or near, normal levels by Week 12 in virologically suppressed patients, and proliferation in response to pokeweed and *Candida* was at normal levels by Week 48 ([Figure 3](#fig3){ref-type="fig"}). Intracellular production of TNF-*α* and IL-2 also increased during the study. Tumor necrosis factor-alpha and IL-2 significantly increased in staphylococcal enterotoxin B-stimulated CD4+ cells of virologically suppressed patients by Week 48; there was no significant change in IFN-*γ* in the stimulated CD4+ cells ([Figure 4](#fig4){ref-type="fig"}).

4. Discussion {#sec4}
=============

Few published studies within clinical trials have prospectively assessed in vitro changes in immune function as measured by lymphocyte proliferation \[[@B1], [@B42]\], and none of these assessed intracellular cytokine production in response to ARV therapy. This substudy from the GRACE trial evaluated T-cell function in a racially diverse, treatment-experienced population comprised of more than 30% women. As expected, based on results from previous studies \[[@B4], [@B16], [@B39]\], DRV/r-based therapy resulted in increases in CD4+ cell counts and decreases in CD8+ counts in virologically suppressed patients, with an improved CD4+/CD8+ ratio. In addition, we found that DRV/r-based ARV therapy was associated with progressive functional immune recovery over 48 weeks in virologically suppressed patients, as demonstrated by improved lymphocyte response to mitogens and recall antigens. This suggests that not only do the CD4+ cell counts of HIV-1-infected patients improve during DRV/r-based therapy, but their ability to respond in vitro to immune stimuli may improve as well. Results from this report are consistent with a recent study that demonstrated significant decreases in immune activation and apoptosis in CD4+ and CD8+ T cells and a decrease in immune CD8+ senescence following ARV therapy \[[@B22]\].

While there have been studies evaluating the influence of ARV therapy on immune parameters, data typically represent class-specific rather than regimen-specific treatment approaches. For example, therapy with integrase inhibitors has been shown to result in larger CD4+ cell count increases compared with other ARV classes \[[@B38], [@B13], [@B40]\]. The work shown here represents a regimen-specific study, with combination DRV/r treatment in addition to an optimized background regimen that could differ across patients. Unfortunately, we cannot assess differences between regimens, as our study was not comparative.

The reduction in T-cell activation seen here has previously been shown to correlate with the reduction in viral load, as well as an improved response to recall antigens \[[@B4]\]. The observed HIV-1-induced increase in apoptotic CD95+/CD4+ cells has been suggested to be independent of ARV activity; the PI saquinavir has been shown to decrease CD95 expression in CD4+ cells from healthy donors whose cells were previously briefly incubated with HIV-1 virus \[[@B12]\]. Although anti-CD95-induced apoptosis declines with therapy, this change is only occasionally associated with a reduction in expression of CD95 on T lymphocytes \[[@B17]\]. It is thus not surprising that in our study CD95 expression on T cells did not decline. In the GRACE study, no improvement in the CD4+/CD28− or CD8+/CD28− phenotype was seen, consistent with other studies that have suggested that CD28 expression is not normalized in HIV-1--infected patients who have undergone up to 3 years of ARV therapy \[[@B29], [@B35]\].

One possible limitation to this study is the small sample size, which may limit data interpretation. The study aimed to enroll 50 women and 50 men, but, due to a delayed start date, after initiation of the GRACE study, the patient pool for this substudy was limited and the enrollment goal was not reached. Nonetheless, the data obtained are similar to those of other trials. Both immune phenotype and function of CD4+ and CD8+ cells were significantly improved in treatment-experienced patients receiving DRV/r-based therapy, as evidenced by positive changes in the capacity to proliferate and the expression of intracellular cytokines by CD4+ cells. The functional recovery observed in virologically suppressed patients, as assessed by proliferative response and intracellular cytokine expression, was also seen in nonsuppressed patients, although to a lesser degree.

Antiretroviral therapy has been available for 25 years; however, there has been limited research on immune recovery after long-term treatment. Furthermore, the focus of immune recovery has historically been an assessment of CD4+ cell counts. In the current study, in addition to the evaluation of CD4+ cell counts, CD4+ cell activation (CD38+/HLA-DR+, CD95+), function, and senescence (CD28−) were measured as well as CD8+ cell counts, activation, function, and senescence. It should be noted that, as observed in this trial, despite the improvements in immune phenotype and function seen with ARV therapy, complete normalization of CD4+ and CD8+ parameters is rarely achieved in HIV-1-infected individuals \[[@B4], [@B28]\]. However, we hypothesize that there may be some clinical benefit even in patients who do not experience measurable or significant increases in CD4+ cell counts. It is feasible that, in patients with higher baseline CD4 levels, measurable increases in CD4+ cell counts may not be observed \[[@B21]\].

Previous studies have shown that despite CD4+ cell count normalization, the pretreatment nadir CD4+ count and level of CD28 CD4+ coexpressing lymphocytes determine ongoing immune competence, including responses to immunization \[[@B29]\]. Despite the successful HIV therapy noted in the GRACE substudy, there seemed to be a higher frequency of the CD8+ CD28− phenotype. This possible treatment-resistant expansion and persistence of cells with a senescence phenotype may have potential for long-term cardiovascular \[[@B23]\], metabolic, and other aging-associated consequences.

This GRACE substudy demonstrates that DRV/r-based therapy improved CD4+ cell recovery and was associated with progressive functional immune recovery over the 48-week study period. Thus, initiation of ARV therapy may be required not only to restore immune function, but also to diminish the effects of chronic inflammation.

This paper was presented at the 5th International AIDS Society Conference on HIV pathogenesis, Treatment and Prevention. Cape Town, South Africa, July 19--22, 2009, Poster TUPD203.
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![(a) Percent CD4+, (b) percent CD8+, and (c) CD4+/CD8+ ratio in virologically suppressed patients. Line represents median; ^a^Wilcoxon rank-sum test; BL: baseline.](ISRN.AIDS2013-358294.001){#fig1}

![(a) CD4+/CD38+/DR+, (b) CD8+/CD38+/DR+, percentage of apoptotic T cells, (c) CD4+/CD95+, (d) CD8+/CD95+. Line represents median; ^a^Wilcoxon rank-sum test; BL: baseline.](ISRN.AIDS2013-358294.002){#fig2}

![CD4+ lymphocyte proliferation in (a) CD3+/CD28+, (b) phytohemagglutinin, (c) pokeweed, (d) *Candida*, and (e) tetanus. Line represents median; ^a^Wilcoxon rank-sum test; BL: baseline; PHA: phytohemagglutinin.](ISRN.AIDS2013-358294.003){#fig3}

![Staphylococcal enterotoxin B-stimulated cytokine expression in virologically suppressed patients. Line represents median; ^a^Wilcoxon rank-sum test; TNF-*α*: tumor necrosis factor-alpha; IL-2: interleukin-2; IFN-*γ*: interferon-gamma; SEB: staphylococcal enterotoxin B; BL: baseline.](ISRN.AIDS2013-358294.004){#fig4}

###### 

Demographics and baseline characteristics of patients enrolled into the immunology substudy of GRACE.

  ------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                             All HIV+ patients\   Virologically suppressed^a^patients at Wk 48 (*n* = 19)
                                                        (*N* = 32)           
  ----------------------------------------- ----------- -------------------- ---------------------------------------------------------
  Sex, *n* (%)                              Men         19 (59.4)            13 (68.4)

  Women                                     13 (40.6)   6 (31.6)             

  Race, *n* (%)                             Black       15 (46.9)            8 (42.1)

  Hispanic                                  10 (31.3)   6 (31.6)             

  White                                     7 (21.9)    5 (26.3)             

  Mean (SD) viral load, log~10~ copies/mL               4.74 (0.84)          4.76 (0.82)

  Median (range) CD4+ count, cells/mm^3^                191 (2, 463)         222 (2, 398)
  ------------------------------------------------------------------------------------------------------------------------------------

^a^HIV-1 RNA \< 50 copies/mL at Wk 48 (or at Wks 36 and 52 if a Wk 48 sample was not available).

###### 

Immune phenotype over the course of the GRACE immunology substudy.

  Median (range)        Baseline            Wk 12               Wk 48                                                       
  --------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  CD4+ (%)              15 (1, 33)          15 (1, 33)          16 (2, 36)          17 (2, 36)          21 (3, 40)          21 (5, 40)
  CD8+ (%)              60.5 (39, 83)       62 (42, 83)         59 (35, 84)         55 (36, 84)         50 (27, 87)         49 (27, 87)
  CD4+/CD8+ ratio (%)   0.22 (0.01, 0.70)   0.22 (0.01, 0.70)   0.30 (0.03, 1.00)   0.36 (0.03, 1.00)   0.41 (0.04, 1.21)   0.52 (0.08, 1.21)
  CD4+/CD38+/DR+ (%)    22.5 (10, 88)       22 (10, 88)         19 (9, 76)          18 (9, 53)          13 (2, 36)          11 (2, 36)
  CD8+/CD38+/DR+ (%)    48.5 (18, 76)       47 (18, 76)         36.5 (11, 71)       34 (11, 62)         25 (4, 68)          22 (4, 52)
  CD4+/CD95+ (%)        15 (1, 35)          16 (1, 35)          21 (3, 38)          22 (3, 38)          23 (4, 41)          24 (6, 41)
  CD8+/CD95+ (%)        71.5 (40, 87)       70 (40, 87)         69.5 (44, 88)       66 (44, 88)         55 (32, 80)         49 (32, 79)
  CD3+/CD4+/CD28+ (%)   93 (46, 99)         95 (56, 99)         94 (67, 100)        94 (70, 100)        96 (67, 99)         96 (67, 99)
  CD3+/CD8+/CD28+ (%)   59.5 (39, 86)       62 (39, 85)         50 (39, 79)         50.5 (39, 79)       56 (23, 82)         56 (35, 82)

^a^ *n* = 32 at baseline, *n* = 30 at Wk 12 and *n* = 25 at Wk 48; ^b^HIV-RNA \< 50 copies/mL at Wk 48 (or at Wks 36 and 52 if a Wk 48 sample was not available), *n* = 19.
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